COST-EFFECTIVENESS OF SECUKINUMAB FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN THE UK

被引：1
|
作者：
Emery, P. [1 ]
van Keep, M. [2 ]
Beard, S. M. [3 ]
Graham, C. N. [4 ]
Miles, L. [4 ]
Jugl, S. M. [5 ]
Gunda, P. [6 ]
Halliday, A. [7 ]
Marzo-Ortega, H. [8 ]
机构：
[1] Univ Leeds, Leeds, W Yorkshire, England
[2] BresMed Netherlands BV, Utrecht, Netherlands
[3] BresMed, Sheffield, S Yorkshire, England
[4] RTI Hlth Solut, Res Triangle Pk, NC USA
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[7] Novartis Pharmaceut UK Ltd, Camberley, Surrey, England
[8] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.765
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS44
引用
收藏
页码：A534 / A534
页数：1
相关论文
共 50 条
  • [1] Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
    Emery, Paul
    Van Keep, Marjolijn
    Beard, Steve
    Graham, Chris
    Miles, LaStella
    Jugl, Steffen Marc
    Gunda, Praveen
    Halliday, Anna
    Marzo-Ortega, Helena
    PHARMACOECONOMICS, 2018, 36 (08) : 1015 - 1027
  • [2] Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
    Paul Emery
    Marjolijn Van Keep
    Steve Beard
    Chris Graham
    LaStella Miles
    Steffen Marc Jugl
    Praveen Gunda
    Anna Halliday
    Helena Marzo-Ortega
    PharmacoEconomics, 2018, 36 : 1015 - 1027
  • [3] COST-EFFECTIVENESS OF SECUKINUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS IN BRAZIL
    Libanore, A.
    Huerta, C.
    Tozato, C.
    VALUE IN HEALTH, 2020, 23 : S221 - S221
  • [4] Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
    Purmonen, Timo
    Puolakka, Kari
    Mishra, Dinesh
    Gunda, Praveen
    Martikainen, Janne
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 159 - 168
  • [5] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS: A CANADIAN PERSPECTIVE
    Chiva-Razavi, S.
    Jain, M.
    Graham, C. N.
    Miles, L.
    Nikoglou, E.
    Gunda, P.
    VALUE IN HEALTH, 2017, 20 (09) : A533 - A534
  • [6] COST-EFFECTIVENESS OF SECUKINUMAB FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN THE UK
    Kirkham, B.
    Buchanan, V
    Sullivan, W.
    Graham, C. N.
    Miles, L.
    Jugl, S. M.
    Gunda, P.
    Halliday, A.
    VALUE IN HEALTH, 2017, 20 (09) : A536 - A536
  • [7] THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS TUMOUR NECROSIS FACTOR a INHIBITOR BIOSIMILARS FOR ANKYLOSING SPONDYLITIS IN THE UK
    Marzo-Ortega, Helena
    Halliday, Anna
    Jugl, Steffen
    Mokashi, Soniya
    Gunda, Praveen
    Graham, Chris
    Miles, LaStella
    Beard, Steve
    van Keep, Marjolijn
    RHEUMATOLOGY, 2017, 56 : 92 - 92
  • [8] COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A SPANISH PERSPECTIVE
    Monteagudo, I
    Navarro-Ruiz, A.
    Khare, A.
    Gunda, P.
    Blanch, C.
    VALUE IN HEALTH, 2019, 22 : S421 - S421
  • [9] COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: AN ARGENTINEAN PERSPECTIVE
    Citera, Gustavo
    Bianculli, Pablo Manuel
    Khare, Ankur
    Jain, Minal
    Aiello, Eleonora
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S117 - S117
  • [10] Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective
    Goeree, Ron
    Chiva-Razavi, Sima
    Gunda, Praveen
    Jain, Minal
    Jugl, Steffen M.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 45 - 52
12345